Delivery strategies for sustained drug release in the lungs

Advanced Drug Delivery Reviews

Volumn 75, Issue , 2014, Pages 81-91

  Loira Pastoriza, Cristina ^a   Todoroff, Julie ^a   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Liposomes; PEGylation; Polymeric carriers; Pulmonary drug delivery; Sustained release strategies

Indexed keywords

DISEASE CONTROL; DRUG PRODUCTS; LIPOSOMES; MACROPHAGES; PROTEINS; TARGETED DRUG DELIVERY;

AERODYNAMIC PROPERTIES; HIGH PROTEIN LOADINGS; LIPOPHILIC COMPOUNDS; PEGYLATION; POLYMERIC CARRIERS; PULMONARY DRUG DELIVERY; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE;

CONTROLLED DRUG DELIVERY;

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CAMPTOTHECIN; CHITOSAN; CIPROFLOXACIN; CYCLOSPORIN A; DENDRIMER; DOXORUBICIN; EXENDIN 4; FENTANYL; FLUTICASONE; INSULIN; LIPOSOME; MACROGOL; NANOCARRIER; PACLITAXEL; POLYETHYLENE GLYCOL DISTEAROYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; POLYMERIC NANOPARTICLE; SOLID LIPID NANOPARTICLE; THYMOPENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; DRUG CARRIER;

AEROSOL; COLLOID; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG UPTAKE; DRY POWDER INHALER; HUMAN; LUNG; LUNG ALVEOLUS MACROPHAGE; NANOENCAPSULATION; NANOMEDICINE; NANOPHARMACEUTICS; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; RESPIRATORY SYSTEM; REVIEW; SUSTAINED DRUG RELEASE; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG RELEASE; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PHARMACOKINETICS;

ADMINISTRATION, INHALATION; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LUNG;

EID: 84908230554     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.017     Document Type: Review

References (133)

1. Zhou Q.T., Tang P., Leung S.S., Chan J.G., Chan H.K. Emerging inhalation aerosol devices and strategies: where are we headed?. Adv. Drug Deliv. Rev. 2014, (in press). 10.1016/j.addr.2014.03.006.
2. Todoroff J., Vanbever R. Fate of nanomedicines in the lungs. Curr. Opin. Colloid Interface Sci. 2011, 16:246-254.
3. Baginski L., Tachon G., Falson F., Patton J.S., Bakowsky U., Ehrhardt C. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:89-101.
4. Yamahara H., Morimoto K., Lee V.H., Kim K.J. Effects of protease inhibitors on vasopressin transport across rat alveolar epithelial cell monolayers. Pharm. Res. 1994, 11:1617-1622.
5. Suri R. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs 2005, 19:135-144.
6. (in). http://www.insmed.com.
7. (in). http://clinicaltrials.gov/ct2/results?term=NCT01515007&Search=Search.
8. (in). http://clinicaltrials.gov/ct2/results?term=NCT00177710.
9. (in). http://clinicaltrials.gov/ct2/results?term=NCT00263315&Search=Search.
10. http://clinicaltrials.gov/ct2/results?term=NCT00791804&Search=Search.
11. http://clinicaltrials.gov/ct2/results?term=NCT00250120.
12. http://clinicaltrials.gov/ct2/results?term=NCT01650545.
13. Hinds W.C. Uniform particle motion. Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles 1999, 53-55.
14. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Respir. Crit. Care Med. 2005, 172:1497-1504.
15. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15μm. J. Aerosol Sci. 1986, 17:811-825.
16. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., Mintzes J., Deaver D., Lotan N., Langer R. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
17. Crowder T.M., Rosati J.A., Schroeter J.D., Hickey A.J., Martonen T.B. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 2002, 19:239-245.
18. Watanabe M., Okada M., Kudo Y., Tonori Y., Niitsuya M., Sato T., Aizawa Y., Kotani M. Differences in the effects of fibrous and particulate titanium dioxide on alveolar macrophages of Fischer 344 rats. J. Toxicol. Environ. Health A 2002, 65:1047-1060.
19. Cohen B.S., Xiong J.Q., Fang C.P., Li W. Deposition of charged particles on lung airways. Health Phys. 1998, 74:554-560.
20. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
21. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 2004, 1:338-344.
22. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
23. Lombry C., Edwards D.A., Préat V., Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L1002-L1008.
24. Bosquillon C. Drug transporters in the lung - Do they play a role in the biopharmaceutics of inhaled drugs?. J. Pharm. Sci. 2010, 99:2240-2255.
25. Nakanishi T., Hasegawa Y., Haruta T., Wakayama T., Tamai I. In vivo evidence of organic cation transporter-mediated tracheal accumulation of the anticholinergic agent ipratropium in mice. J. Pharm. Sci. 2013, 102:3373-3381.
26. Al-Jayyoussi G., Price D.F., Francombe D., Taylor G., Smith M.W., Morris C., Edwards C.D., Eddershaw P., Gumbleton M. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J. Pharm. Sci. 2013, 102:3382-3394.
27. Matsukawa Y., Lee V.H., Crandall E.D., Kim K.J. Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J. Pharm. Sci. 1997, 86:305-309.
28. Sangwan S., Agosti J.M., Bauer L.A., Otulana B.A., Morishige R.J., Cipolla D.C., Blanchard J.D., Smaldone G.C. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J. Aerosol. Med. Pulm. Drug Deliv. 2001, 14.
29. Richards R., Haas A., Simpson S., Britten A., Renwick A., Holgate S. Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. Thorax 1988, 43:611-616.
30. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996, 19:3-36.
31. Semmler-Behnke M., Takenaka S., Fertsch S., Wenk A., Seitz J., Mayer P., Oberdorster G., Kreyling W.G. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ. Health Perspect. 2007, 115:728-733.
32. Geiser M., Casaulta M., Kupferschmid B., Schulz H., Semmler-Behnke M., Kreyling W. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am. J. Respir. Cell Mol. Biol. 2008, 38:371-376.
33. Beck-Broichsitter M., Merkel O.M., Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J. Control. Release 2012, 161:214-224.
34. Hofmann W., Asgharian B. The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol. Sci. 2003, 73:448-456.
35. Foster W.M., Langenback E., Bergofsky E.H. Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1980, 48:965-971.
36. Moller W., Felten K., Sommerer K., Scheuch G., Meyer G., Meyer P., Haussinger K., Kreyling W.G. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am. J. Respir. Crit. Care Med. 2008, 177:426-432.
37. Roy I., Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 2010, 6:237-244.
38. Bonacucina G., Cespi M., Misici-Falzi M., Palmieri G.F. Colloidal soft matter as drug delivery system. J. Pharm. Sci. 2009, 98:1-42.
39. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - A review. Int. J. Pharm. 2011, 415:34-52.
40. Bibby D.C., Davies N.M., Tucker I.G. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int. J. Pharm. 2000, 197:1-11.
41. Ungaro F., D'Angelo I., Miro A., La Rotonda M.I., Quaglia F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J. Pharm. Pharmacol. 2012, 64:1217-1235.
42. Beck-Broichsitter M., Rieger M., Reul R., Gessler T., Seeger W., Schmehl T. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur. J. Pharm. Biopharm. 2013, 84:106-114.
43. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
44. Upadhyay D., Scalia S., Vogel R., Wheate N., Salama R.O., Young P.M., Traini D., Chrzanowski W. Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm. Res. 2012, 29:2456-2467.
45. Tolman J.A., Williams Iii R.O. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev. Ind. Pharm. 2010, 36:1-30.
46. Thorsson L., Edsbäcker S., Källén A., Löfdahl C.G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. J. Clin. Pharmacol. 2001, 52:529-538.
47. Wang J., Ben-Jebria A., Edwards D.A. Inhalation of estradiol for sustained systemic delivery. J Aerosol. Med. 1999, 12:27-36.
48. Vanbever R., Ben-Jebria A., Mintzes J.D., Langer R., Edwards D.A. Sustained release of insulin from insoluble inhaled particles. Drug Dev. Res. 1999, 48:178-185.
49. El-Gendy N., Pornputtapitak W., Berkland C. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. Eur. J. Pharm. Sci. 2011, 44:522-533.
50. Ben-Jebria A., Chen D., Eskew M.L., Vanbever R., Langer R., Edwards D.A. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm. Res. 1999, 16:555-561.
51. Vanbever R., Mintzes J.D., Wang J., Nice J., Chen D., Batycky R., Langer R., Edwards D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 1999, 16:1735-1742.
52. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24:411-437.
53. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., Kissel T., Seeger W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol. 2006, 215:100-108.
54. Rawat A., Majumder Q.H., Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J. Control. Release 2008, 128:224-232.
55. Dhanda D.S., Tyagi P., Mirvish S.S., Kompella U.B. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J. Control. Release 2013, 168:239-250.
56. Oh Y.J., Lee J., Seo J.Y., Rhim T., Kim S.H., Yoon H.J., Lee K.Y. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J. Control. Release 2011, 150:56-62.
57. Doan T.V.P., Grégoire N., Lamarche I., Gobin P., Marchand S., Couet W., Olivier J.C. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. Eur. J. Pharm. Sci. 2013, 48:223-230.
58. de Boer A.H., Hagedoorn P., Westerman E.M., Le Brun P.P.H., Heijerman H.G.M., Frijlink H.W. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer(r)) for high powder doses. Eur. J. Pharm. Sci. 2006, 28:171-178.
59. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using pulmosphere(tm) technology. J. Aerosol. Med. Pulm. Drug Deliv. 2011, 24:175-182.
60. Ungaro F., d'Emmanuele di Villa Bianca R., Giovino C., Miro A., Sorrentino R., Quaglia F., La Rotonda M.I. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J. Control. Release 2009, 135:25-34.
61. Fu J., Fiegel J., Krauland E., Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 2002, 23:4425-4433.
62. Lee J., Oh Y.J., Lee S.K., Lee K.Y. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J. Control. Release 2010, 146:61-67.
63. Gupta V., Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. Int. J. Pharm. 2011, 413:51-62.
64. De Rosa G., Larobina D., Immacolata La Rotonda M., Musto P., Quaglia F., Ungaro F. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-β-cyclodextrin system. J. Control. Release 2005, 102:71-83.
65. El-Sherbiny I.M., McGill S., Smyth H.D.C. Swellable microparticles as carriers for sustained pulmonary drug delivery. J. Pharm. Sci. 2010, 99:2343-2356.
66. Jaspart S., Bertholet P., Piel G., Dogne J.M., Delattre L., Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 2007, 65:47-56.
67. Mezzena M., Scalia S., Young P.M., Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J. 2009, 11:771-778.
68. Möbus K., Siepmann J., Bodmeier R. Zinc-alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying. Eur. J. Pharm. Biopharm. 2012, 81:121-130.
69. Scalia S., Haghi M., Losi V., Trotta V., Young P.M., Traini D. Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. Eur. J. Pharm. Sci. 2013, 49:278-285.
70. Tawfeek H., Khidr S., Samy E., Ahmed S., Murphy M., Mohammed A., Shabir A., Hutcheon G., Saleem I. Poly(glycerol adipate-co-Ω-pentadecalactone) spray-dried microparticles as sustained release carriers for pulmonary delivery. Pharm. Res. 2011, 28:2086-2097.
71. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol. 2011, 9:55.
72. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Release 2003, 86:131-144.
73. Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12001-12005.
74. Ungaro F., d'Angelo I., Coletta C., d'Emmanuele di Villa Bianca R., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release 2012, 157:149-159.
75. Lee C., Choi J.S., Kim I., Oh K.T., Lee E.S., Park E.S., Lee K.C., Youn Y.S. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int. J. Nanomedicine 2013, 8:2975-2983.
76. Yeh T.-H., Hsu L.-W., Tseng M.T., Lee P.-L., Sonjae K., Ho Y.-C., Sung H.-W. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 2011, 32:6164-6173.
77. Lai S.K., Wang Y.-Y., Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61:158-171.
78. Sanders N., Rudolph C., Braeckmans K., De Smedt S.C., Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 2009, 61:115-127.
79. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
80. Sahib M.N., Darwis Y., Peh K.K., Abdulameer S.A., Fung Tan Y.T. Incorporation of beclomethasone dipropionate into polyethylene glycol-diacyl lipid micelles as a pulmonary delivery system. Drug Dev. Res. 2012, 73:90-105.
81. Gill K.K., Nazzal S., Kaddoumi A. Paclitaxel loaded PEG5000-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur. J. Pharm. Biopharm. 2011, 79:276-284.
82. Todoroff J., Ucakar B., Inglese M., Vandermarliere S., Fillee C., Renauld J.C., Huygen K., Vanbever R. Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. Eur. J. Pharm. Biopharm. 2013, 84:40-48.
83. Willis L., Hayes D., Mansour H.M. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 2012, 190:251-262.
84. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997, 154:123-140.
85. Finlay W.H., Wong J.P. Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin. Int. J. Pharm. 1998, 167:121-127.
86. Chimote G., Banerjee R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J. Biomed. Mater. Res. B Appl. Biomater. 2010, 94:1-10.
87. Huang W.H., Yang Z.J., Wu H., Wong Y.F., Zhao Z.Z., Liu L. Development of liposomal salbutamol sulfate dry powder inhaler formulation. Biol. Pharm. Bull. 2010, 33:512-517.
88. Chen X., Huang W., Kwan Wong B.C., Yin L., Wong Y.F., Xu M., Yang Z. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomedicine 2012, 7:1139-1148.
89. Waldrep J.C., Arppe J., Jansa K.A., Vidgren M. Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int. J. Pharm. 1998, 160:239-249.
90. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2007, 2:675-688.
91. Hitzman C.J., Elmquist W.F., Wattenberg L.W., Wiedmann T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. 2006, 95:1114-1126.
92. Murata M., Nakano K., Tahara K., Tozuka Y., Takeuchi H. Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. Eur. J. Pharm. Biopharm. 2012, 80:340-346.
93. Shahiwala A., Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech 2004, 5.
94. Hajos F., Stark B., Hensler S., Prassl R., Mosgoeller W. Inhalable liposomal formulation for vasoactive intestinal peptide. Int. J. Pharm. 2008, 357:286-294.
95. Liu F.Y., Shao Z., Kildsig D.O., Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 1993, 10:228-232.
96. Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., Reimer D.C., Pozharov V.P., Minko T. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 2009, 26:382-394.
97. Gaspar M.M., Bakowsky U., Ehrhardt C. Inhaled liposomes - Current strategies and future challenges. J. Biomed. Nanotechnol. 2008, 4:245-257.
98. Gibbons A., McElvaney N.G., Cryan S.A. A dry powder formulation of liposome-encapsulated recombinant secretory leukocyte protease inhibitor (rSLPI) for inhalation: preparation and characterisation. AAPS PharmSciTech 2010, 11:1411-1421.
99. Tang Y., Zhang H., Lu X., Jiang L., Xi X., Liu J., Zhu J. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. Drug Deliv. 2013, (in press). 10.3109/10717544.2013.863526.
100. Bi R., Shao W., Wang Q., Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 2008, 16:639-648.
101. (in). http://clinicaltrials.gov/ct2/results?term=NCT01316276.
102. (in). http://clinicaltrials.gov/ct2/results?term=NCT01315691.
103. (in). http://clinicaltrials.gov/ct2/results?term=NCT01315678.
104. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., Lymp J., Minic P., Quittner A.L., Rubenstein R.C., Young K.R., Saiman L., Burns J.L., Govan J.R.W., Ramsey B., Gupta R. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825.
105. (in). http://clinicaltrials.gov/ct2/results?term=NCT01315236&Search=Search.
106. Li Z., Zhang Y., Wurtz W., Lee J.K., Malinin V.S., Durwas-Krishnan S., Meers P., Perkins W.R. Characterization of nebulized liposomal amikacin (Arikace(tm)) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv. 2008, 21:245-253.
107. Meers P., Neville M., Malinin V., Scotto A.W., Sardaryan G., Kurumunda R., Mackinson C., James G., Fisher S., Perkins W.R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008, 61:859-868.
108. Serisier D.J., Bilton D., De Soyza A., Thompson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
109. Weber S., Zimmer A., Pardeike J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm. 2014, 86:7-22.
110. Liu J., Gong T., Fu H., Wang C., Wang X., Chen Q., Zhang Q., He Q., Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm. 2008, 356:333-344.
111. Nassimi M., Schleh C., Lauenstein H.D., Hussein R., Hoymann H.G., Koch W., Pohlmann G., Krug N., Sewald K., Rittinghausen S., Braun A., Müller-Goymann C. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 2010, 75:107-116.
112. Li Y.-Z., Sun X., Gong T., Liu J., Zuo J., Zhang Z.-R. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm. Res. 2010, 27:1977-1986.
113. Bai S., Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm. Res. 2009, 26:539-548.
114. Mignani S., El Kazzouli S., Bousmina M., Majoral J.-P. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview. Adv. Drug Deliv. Rev. 2013, 65:1316-1330.
115. Inapagolla R., Guru B.R., Kurtoglu Y.E., Gao X., Lieh-Lai M., Bassett D.J.P., Kannan R.M. In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. Int. J. Pharm. 2010, 399:140-147.
116. Ryan G.M., Kaminskas L.M., Kelly B.D., Owen D.J., McIntosh M.P., Porter C.J.H. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol. Pharm. 2013, 10:2986-2995.
117. Kaminskas L.M., McLeod V.M., Ryan G.M., Kelly B.D., Haynes J.M., Williamson M., Thienthong N., Owen D.J., Porter C.J. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control. Release 2014, 183:18-26.
118. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
119. Veronese F.M. PEGylated Protein Drugs: Basic Science and Clinical Applications 2009, Basel, Switzerland.
120. Harris J.M. Poly(ethyleneglycol) chemistry: biotechnical and biomedical applications 1992.
121. Fee C.J., Van Alstine J.M. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug. Chem. 2004, 15:1304-1313.
122. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 2005, 10:1451-1458.
123. Healy A.M., Amaro M.I., Paluch K.J., Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv. Drug Deliv. Rev. 2014, (in press). 10.1016/j.addr.2014.04.005.
124. Working P.K., Newman M.S., Johnson J., Cornacoff J.B. Safety of poly(ethyleneglycol) and poly(ethyleneglycol) derivatives. ACS Symposium Series 1997, 45-59. ACS Publications.
125. Leach C., Kuo M., Bueche B., Fishburn S., Viegas T., Bossard M., Guo L., Bentley M., Hobbs C., Cherrington A. Modifying the pulmonary absorption and retention of proteins through PEGylation. Respir. Drug Deliv. IX 2004, 1:69-77.
126. Niven R.W., Whitcomb K.L., Shaner L., Ralph L.D., Habberfield A.D., Wilson J.V. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF). J. Control. Release 1994, 32:177-189.
127. Niven R.W., Whitcomb K.L., Shaner L., Ip A.Y., Kinstler O.B. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm. Res. 1995, 12:1343-1349.
128. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J. Control. Release 2008, 125:68-75.
129. Lee K.C., Chae S.Y., Kim T.H., Lee S., Lee E.S., Youn Y.S. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul. Pept. 2009, 152:101-107.
130. Koussoroplis S.J., Paulissen G., Tyteca D., Goldansaz H., Todoroff J., Barilly C., Uyttenhove C., Van Snick J., Cataldo D., Vanbever R. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control. Release 2014, 187:91-100.
131. Bayard F.J.C., Thielemans W., Pritchard D.I., Paine S.W., Young S.S., Bäckman P., Ewing P., Bosquillon C. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J. Control. Release 2013, 171:234-240.
132. Xie Y., Aillon K.L., Cai S., Christian J.M., Davies N.M., Berkland C.J., Forrest M.L. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int. J. Pharm. 2010, 392:156-163.
133. Winkler J., Hochhaus G., Derendorf H. How the lung handles drugs. Proc. Am. Thorac. Soc. 2004, 1:356-363.